Addressing potential bias when assessing safety of biologics and JAK inhibitors in atopic dermatitis

Documenti analoghi

• Translating 6‐year trial safety data of upadacitinib in atopic dermatitis into clinical practice
  di: Lian F. van der Gang, et al.
  Pubblicazione: (2026)
• Reassuring evidence on infection risk with dupilumab in atopic dermatitis: Lessons from real‐world evidence
  di: Lian F. van der Gang, et al.
  Pubblicazione: (2025)
• Increasing dosing intervals for biologics in atopic dermatitis‐why, who, when and how?
  di: M. E. Jacobson, et al.
  Pubblicazione: (2025)
• Critical methodological enhancements for JAK inhibitor safety studies in atopic dermatitis
  di: Zheying Huang, et al.
  Pubblicazione: (2025)
• Correspondence to ‘Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis’
  di: Shiuan‐Chih Chen, et al.
  Pubblicazione: (2025)